<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03534648</url>
  </required_header>
  <id_info>
    <org_study_id>C3711002</org_study_id>
    <secondary_id>DDI</secondary_id>
    <secondary_id>2018-000694-70</secondary_id>
    <nct_id>NCT03534648</nct_id>
  </id_info>
  <brief_title>Evaluation of Pharmacokinetic Drug Drug Interaction Between PF-05221304 And PF-06865571 In Healthy Adult Subjects</brief_title>
  <official_title>A Phase 1, Open Label, Two-cohort, Non-randomized Fixed Sequence Study To Evaluate The Pharmacokinetic Drug Drug Interaction Between Pf-05221304 And Pf-06865571 In Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug drug interaction study between PF-05221304 and PF-06865571
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 1, Open Label, Two-cohort, Non-randomized Fixed Sequence Study To Evaluate The
      Pharmacokinetic Drug Drug Interaction Between Pf-05221304 And Pf-06865571 In Healthy Adult
      Subjects
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2018</start_date>
  <completion_date type="Anticipated">July 13, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 13, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arm 1: PF-05221304 Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)</measure>
    <time_frame>Day 7, 0-12 hours and Day 14 0-12 hourss</time_frame>
    <description>Area under the concentration curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 12 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm 1: PF-05221304 Maximum observed concentration from Time Zero to End if Dosing Interval (Cmax)</measure>
    <time_frame>Day 7, 0-12 hours and Day 14 0-12 hours</time_frame>
    <description>Maximum observed concentration from Time Zero to End if Dosing Interval (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm 2: PF-06865571 Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau)</measure>
    <time_frame>Day 7, 0-12 hours and Day 14 0-12 hours</time_frame>
    <description>Area under the concentration curve from time 0 to end of dosing interval (AUCtau), where dosing interval was 12 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm 2: PF-06865571 Maximum observed concentration from Time Zero to End if Dosing Interval (Cmax)</measure>
    <time_frame>Day 7, 0-12 hours and Day 14 0-12 hours</time_frame>
    <description>Maximum observed concentration from Time Zero to End if Dosing Interval (Cmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)</measure>
    <time_frame>Screening up to 28 days after last dose of study medication</time_frame>
    <description>Treatment-emergent AE was any untoward medical occurrence attributed to study drug in a subject who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to Drug was assessed by the investigator (Yes/No). Subjects with multiple occurrences of an AE within a category were counted once within the category.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Effect of PF-05221304 on PF-06865571 PK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Effect of PF-06865571 on PF-05221304 PK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06865571 administered Day 7-14</intervention_name>
    <description>PF-06865571 administered Q12hr on Days 7-14</description>
    <arm_group_label>Effect of PF-05221304 on PF-06865571 PK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06865571 administered Day 1-14</intervention_name>
    <description>PF-06865571 administered Q12hr on Day 7-14</description>
    <arm_group_label>Effect of PF-06865571 on PF-05221304 PK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05221304 administered Day 1-14</intervention_name>
    <description>PF-05221304 administered Q12hr on Days 1-14</description>
    <arm_group_label>Effect of PF-05221304 on PF-06865571 PK</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05221304 administered Day 7-14</intervention_name>
    <description>PF-05221304 administered Q12hr Days 7-14</description>
    <arm_group_label>Effect of PF-06865571 on PF-05221304 PK</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy female subjects of nonchildbearing potential and/or male subjects.

          2. Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lb).

        Exclusion Criteria

          1. Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or
             allergic disease.

          2. Any condition possibly affecting drug absorption.

          3. A positive urine drug test.

          4. Screening supine BP 140 mm Hg (systolic) or 90 mm Hg (diastolic), following at least 5
             minutes of supine rest.

          5. Screening supine 12 lead ECG demonstrating a corrected QT (QTc) interval &gt;450 msec or
             a QRS interval &gt;120 msec.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pfizer Clinical Research Unit</name>
      <address>
        <city>Brussels</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C3711002&amp;StudyName=A+Phase+1%2C+Open+Label%2C+Two-cohort%2C+Non-randomized+Fixed+Sequence+Study++To+Evaluate+The+Pharmacokinetic+Drug+Drug+Interaction+Between+Pf-05221304+And+Pf-06865571+In+Healthy+Adult+Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2018</study_first_submitted>
  <study_first_submitted_qc>May 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2018</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

